Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05990426 · ClinicalTrials.gov registry record · NA
Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy
A NA study of Endometrial Cancer and Uterine Cancer, sponsored by Northwestern University.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05990426: Recruiting NA study of Endometrial Cancer and Uterine Cancer, sponsored by Northwestern University.
NCT05990426 is a NA study of Endometrial Cancer and Uterine Cancer that is actively recruiting participants, run by Northwestern University. The registered enrollment target is 30 participants, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05990426, a NA study of Endometrial Cancer and Uterine Cancer, is actively recruiting participants, sponsored by Northwestern University.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Endometrial cancer is the most common gynecologic cancer and ovarian cancer is the most lethal. The management of both advanced cancers is a combination of chemotherapy and surgery. Standard of care chemotherapeutic treatment for uterine and ovarian cancers is toxic and severely disruptive to the patient's quality of life with the potential for devastating short and long-term side effects. The role of fasting and ketogenic diets has been evaluated in a mixed cancer population and previously shown to be safe. There is no data specifically addressing the impact of a fasting diet regimen on side effects of chemotherapy during treatment for ovarian and endometrial cancers in the front-line setting. The information gathered from this study will inform future trials about the role of time-restricted eating and its impact on side-effects associated with chemotherapy as well as its role in improvement of quality of life for women afflicted with these debilitating diseases.
Primary Outcome
Assessment compliance will be defined as missing no more than 75% of indicated Biosense measurement (i.e. no more than number of cycles × 7 measurements), which roughly corresponds to no more than 1 missed measurement per day of fasting period. The study will be considered feasible in terms of assessment compliance if at least 80% of all patients are compliant.
Conditions Studied
Interventions
- BEHAVIORAL FAST Intervention
Study Locations (1)
Illinois
- Northwestern Memorial Hospital - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-10-16 |
| Est. Completion | 2026-08 |
| Phase | NA |
What NCT05990426 shows while recruiting
NCT05990426 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (94% lower).
The record links to 3 conditions, with Endometrial Cancer appearing as the primary indexed condition, and to 1 intervention - of which FAST Intervention is the first listed.
NCT05990426 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT05990426 about?
NCT05990426 is a clinical study titled "Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy". Endometrial cancer is the most common gynecologic cancer and ovarian cancer is the most lethal. The management of both advanced cancers is a combination of chemotherapy and surgery. Standard of care chemotherapeutic treatment for uterine and ovarian cancers is toxic and severely disruptive to the pa...
What is the current status of trial NCT05990426?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2023-10-16. Estimated completion is 2026-08.
What conditions does trial NCT05990426 study?
This clinical trial studies the following conditions: Endometrial Cancer, Uterine Cancer, Ovary Cancer.
What interventions are being tested in trial NCT05990426?
The interventions under investigation include: FAST Intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT05990426?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05990426 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05990426's enrollment target sits among peer trials
30 147th of 181 higher than 28 of 181 other Endometrial Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Endometrial Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ASk Questions in GYnecologic Oncology (ASQ-GYO)
RECRUITING · NA
-
MCC-24-GYN-11: Comparison of Nodal Sampling in Endometrial Cancer
RECRUITING · NA
-
Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)
RECRUITING · NA
-
A Study of Multiparametric Ultrasound Imaging (mpUS) for People With Endometrial Cancer
RECRUITING · NA
-
ctDNA Testing to Inform Standard-of-Care Treatment Decisions in People With Endometrial Cancer
RECRUITING · NA
-
Use of an Intrauterine Manipulator and Its Correlation with Positive Peritoneal Cytology in Early Stage Endometrial Cancers
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI